Lista de obras - Marina Bolzoni - Dominio Público Uruguay

Angiogenesis and Multiple Myeloma ⬇️

artículo científico publicado el 7 de julio de 2011

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

artículo científico

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

artículo científico publicado en 2010

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

artículo científico publicado en 2016

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

artículo científico publicado en 2016

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

artículo científico publicado en 2009

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation

artículo científico publicado en 2017

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

artículo científico publicado en 2016

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

artículo científico publicado en 2010

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

artículo científico publicado en 2013

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

artículo científico publicado en 2017

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

artículo científico publicado en 2012

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.

artículo científico publicado en 2012

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

artículo científico publicado en 2010

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

artículo científico publicado en 2015

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD

artículo científico publicado en 2018

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

artículo científico publicado en 2012

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model

artículo científico publicado en 2015

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

artículo científico publicado en 2015

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations

article

Possible targets to treat myeloma-related osteoclastogenesis.

artículo científico publicado en 2018

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy

artículo científico publicado en 2018

The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors

artículo científico publicado en 2015

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

artículo científico publicado en 2015

The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38

artículo científico publicado en 2018

The osteoblastic niche in the context of multiple myeloma

artículo científico publicado en 2014

The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma

scientific article published on 18 January 2017

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

artículo científico publicado en 2010

Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.

artículo científico publicado en 2014

Lista de obras de Marina Bolzoni

Angiogenesis and Multiple Myeloma ⬇️

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations

Possible targets to treat myeloma-related osteoclastogenesis.

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy

The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38

The osteoblastic niche in the context of multiple myeloma

The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.